News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EXCLUSIVE: SGS Life Science Services (SGSN) Will Double Headcount in Shanghai, EVP Tells BioSpace (DHX)



6/25/2015 1:16:11 PM

EXCLUSIVE: SGS Will Double Headcount in Shanghai, CEO Tells BioSpace
June 25, 2015
By Riley McDermid, BioSpace.com Breaking News Sr. Editor

SGS Life Science Services (SGSN)’s new laboratory in a Shanghai will almost double its staff to 135 by the end of 2015, the company’s executive vice president told BioSpace (DHX) Thursday.

The number of workers at the Shanghai facility has grown from 74 in 2014, to a current headcount of 120, with 135 due to be signed by the end of 2015. SGS is one of the world’s largest inspection, verification, testing and certification companies.

Zoltan Szabo, acting executive vice president, for Life Science Services at SGS, said in an interview that the new 3,200-square-meter site in Shanghai is a sign of the company’s latest commitment to stocking state-of-the-art equipment. SGS also recently announced it would expand another site in the Parisian suburb of Villeneuve LaGarenne

“The recent developments in our laboratories in Villeneuve LaGarenne and Shanghai reflect our strategy and commitment to the market,” Szabo told BioSpace. “Namely, this involves ensuring state of the art facilities by upgrading the offering for quality control testing of small molecule drugs.

Both sites will allow the company to offer new services via a compound laboratory designed to test products such as antibodies and hormones. While the testing of these compounds involves physical and chemical analyses, based upon pharmacopeia methods and/or client methods, greater controls are implemented to avoid cross contamination.
  Related Jobs  
  Scientific Data Manager - Invitae
  Senior Scientist - Mylan
  Director, Clinical Operations - OXiGENE
  Research Associate II - Synthetic Genomics
  Associate Scientist II - MedImmune
  Mechanical Engineer II - Bio-Rad
  View More Jobs


It will also allow SGS to grab market share in areas of production where it had not previously had much of a presence, Szabo told BioSpace. The Shanghai campus will have new office space, as well as a drug compatibility study lab designed to meet regulatory requirements.

“Additionally, this also includes expanding our portfolio of services at our sites to address the growing biologics market,” he said.

SGS will now offer services in Shanghai that include cytotoxicity, cell-based assay, endotoxin and ELISA testing.

“The plans for investment and expansion at the Shanghai facility that we originally announced in July 2014 have been superseded by demand from international and domestic customers, particularly in the Extractables and Leachables testing market” said Andy Yi, general manager, SGS Life Science Services, Shanghai.

SGS has 18 laboratories offering contract analytical and bioanalytical services to most of the top 10 largest biotech and biopharmas, with sites in North America, Europe and Asia. It has more than 80,000 employees at 1,650 offices and laboratories globally.

SGS is the world’s leading inspection, verification, testing and certification company. SGS is recognised as the global benchmark for quality and integrity. With more than 80,000 employees, SGS operates a network of over 1,650 offices and laboratories around the world.


As Rumors Swirl About GlaxoSmithKline Bid, Who Could Suitors Be?
Rumors are swirling that Swiss-based Roche (RHHBY) and U.S.-based Johnson & Johnson (JNJ) are eying the U.K. company for approximately $143 billion. But Roche and J&J aren’t the only companies though who have been thought could go after the elephant that is Glaxo.

Last month there was buzz that Pfizer Inc. (PFE) was considering acquiring Glaxo, a year after it failed to acquire AstraZeneca PLC (AZN). Just this month over a third of respondents in a poll conducted by BioSpace (DHX) believe that AstraZeneca PLC could be in the running to acquire struggling GlaxoSmithKline (GSK).

So BioSpace wants to ask our readers again what they predict for this new dealmaking bonanza. Will Glaxo go—and if so, to whom?


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES